ArticleClinical and experimental nephrology2026
Attribute-based cross-classification reveals sex- and age-specific prognostic impact of anemia in ADPKD.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundAnemia is less prevalent in autosomal dominant polycystic kidney disease (ADPKD) owing to preserved erythropoietin production. However, its impact on kidney prognosis remains unclear. Given sex-related differences in hemoglobin (Hb) levels, we hypothesized that the prognostic relevance of anemia may vary by sex and age. Therefore, we aimed to identify subgroup-specific risk patterns using an attribute-based cross-classification approach to support individualized anemia management in ADPKD.
methodsWe analyzed 552 Japanese patients with ADPKD from a single-center cohort. The primary outcome was a ≥ 30% decline in the estimated glomerular filtration rate (eGFR) or initiation of renal replacement therapy. Cox regression analysis was used to assess the association between Hb and kidney outcomes. Subgroup analyses were performed using cross-classification by sex and age (< 50 or ≥ 50 years). Anemia was defined using multiple Hb thresholds (< 11, < 12, and < 13 g/dL).
resultsLower Hb levels were independently associated with worse renal outcomes (hazard ratio [HR] per 1 g/dL increase: 0.83). Cross-classified analyses revealed distinct risk patterns. Anemia (Hb level < 13.0 g/dL) significantly increased the risk in young (HR: 2.92) and old men (HR: 3.84). In women, anemia defined as a Hb level < 12.0 g/dL was associated with adverse outcomes in both age groups (HR: 1.98 in < 50 years; HR: 2.08 in ≥ 50 years).
conclusionAnemia is a significant prognostic marker for kidney disease progression in ADPKD. Its prognostic impact differs by sex and age, suggesting the need for attribute-based, individualized hemoglobin thresholds rather than uniform cutoffs, to optimize risk stratification and clinical assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.